BioCryst Pharmaceuticals (BCRX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.30
- EPS estimate
- $0.15
- EPS surprise
- +94.55%
- Revenue surprise
- +19.08%
- Revenue
- $218.3M
- Revenue estimate
- $183.3M
- Reported
- Aug 5, 2026
BioCryst Pharmaceuticals reported Q2 2026 results on August 5, 2026. Earnings per share were $0.30, ahead of the $0.15 estimate by 94.55%. Revenue was $218.3 million, beating the $183.3 million consensus by 19.08%. Compared with Q2 2025, EPS rose from $0.02 and revenue grew about 34% from $163.4 million.
The longer record shows a move from steady losses to profit, with large swings lately. BioCryst lost money in every quarter from Q3 2021 through Q4 2024. Fiscal 2025 was its first profitable year in the table, at $1.20 per share, as revenue nearly doubled to $874.9 million. Q4 2025 stands out, with $406.6 million in revenue and EPS of $1.12, both highs in the table. Q1 2026 then brought a loss of $2.98 per share, the largest in the table, so the first half of 2026 shows a combined loss of $2.68 even though revenue rose about 21%. BioCryst beat EPS estimates in 12 of the last 20 quarters.
Q3 results came between November 1 and November 4 in each of the past five years. That points to early November 2026 for the next report, which will show whether the Q2 profit carries into the third quarter.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | $0.15 | $0.30 | +94.55% | $218.3M | SEC |
| Q1 2026 | May 6, 2026 | $0.04 | −$2.98 | −6826.86% | $156.4M | SEC |
| Q4 2025 | Feb 26, 2026 | $0.05 | $1.12 | +2218.84% | $406.6M | SEC |
| Q3 2025 | Nov 3, 2025 | $0.04 | $0.06 | +50.75% | $159.4M | SEC |
| Q2 2025 | Aug 4, 2025 | $0.01 | $0.02 | +185.71% | $163.4M | SEC |
| Q1 2025 | May 5, 2025 | −$0.07 | $0.00 | +100.00% | $145.5M | SEC |
| Q4 2024 | Feb 24, 2025 | −$0.05 | −$0.13 | −155.40% | $131.5M | SEC |
| Q3 2024 | Nov 4, 2024 | −$0.07 | −$0.07 | −2.94% | $117.1M | SEC |
| Q2 2024 | Aug 5, 2024 | −$0.17 | −$0.06 | +65.32% | $109.3M | SEC |
| Q1 2024 | May 6, 2024 | −$0.21 | −$0.17 | +18.78% | $92.8M | SEC |
| Q4 2023 | Feb 26, 2024 | −$0.25 | −$0.31 | −26.07% | $93.4M | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.25 | −$0.19 | +22.45% | $86.7M | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.23 | −$0.40 | −70.94% | $82.5M | SEC |
| Q1 2023 | May 3, 2023 | −$0.30 | −$0.28 | +6.26% | $68.8M | SEC |
| Q4 2022 | Feb 21, 2023 | −$0.17 | −$0.38 | −128.37% | $79.5M | SEC |
| Q3 2022 | Nov 1, 2022 | −$0.29 | −$0.23 | +19.44% | $75.8M | — |
| Q2 2022 | Aug 4, 2022 | −$0.34 | −$0.32 | +6.87% | $65.5M | — |
| Q1 2022 | May 5, 2022 | −$0.36 | −$0.40 | −10.34% | $49.9M | — |
| Q4 2021 | Feb 23, 2022 | −$0.30 | −$0.10 | +66.10% | $47.2M | — |
| Q3 2021 | Nov 3, 2021 | −$0.29 | −$0.33 | −12.74% | $41.0M | — |
Quarterly revenue
Frequently asked questions
When did BioCryst Pharmaceuticals (BCRX) last report earnings?
BioCryst Pharmaceuticals last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did BCRX beat earnings estimates?
Yes. BioCryst Pharmaceuticals reported EPS of $0.30 for Q2 2026 against a $0.15 estimate — a 94.55% beat.
How much revenue did BCRX report last quarter?
BioCryst Pharmaceuticals reported $218.3M in revenue for Q2 2026, against a consensus estimate of $183.3M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.